Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis

Bibliography

• Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013;54:551-63
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Medical management of refractory epilepsy--practical treatment with novel antiepileptic drugs. Epilepsia 2014;55(Suppl 1):3-8
   PubMed Web of Science ®Google Scholar
• Berg AT. The natural history of mesial temporal lobe epilepsy. Curr Opin Neurol 2008;21:173-8
   PubMed Web of Science ®Google Scholar
• Semah F, Lamy C, Demeret S. Hippocampal sclerosis and other hippocampal abnormalities in the early identification of candidates for epilepsy surgery. Arch Neurol 2002;59:1042-3; author reply 43
   PubMed Web of Science ®Google Scholar
• Malmgren K, Thom M. Hippocampal sclerosis--origins and imaging. Epilepsia 2012;53(Suppl 4):19-33
   PubMed Web of Science ®Google Scholar
• D’Alessio L, Giagante B, Ibarra V, et al. Analysis of psychotic disorders in patients with refractory partial epilepsy, psychiatric diagnoses and clinical aspects. Actas Esp Psiquiatr 2008;36:138-43
   PubMed Web of Science ®Google Scholar
• Thom M. Hippocampal sclerosis: progress since Sommer. Brain Pathol 2009;19:565-72
   PubMed Web of Science ®Google Scholar
• de Lanerolle NC, Kim JH, Williamson A, et al. A retrospective analysis of hippocampal pathology in human temporal lobe epilepsy: evidence for distinctive patient subcategories. Epilepsia 2003;44:677-87
   PubMed Web of Science ®Google Scholar
• Blumcke I, Thom M, Aronica E, et al. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia 2013;54:1315-29
   PubMed Web of Science ®Google Scholar
• Schmidt D, Sillanpaa M. Evidence-based review on the natural history of the epilepsies. Curr Opin Neurol 2012;25:159-63
   PubMed Web of Science ®Google Scholar
• Tellez-Zenteno JF, Hernandez-Ronquillo L, Buckley S, et al. A validation of the new definition of drug-resistant epilepsy by the International League Against Epilepsy. Epilepsia 2014;55:829-34
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 2010;19:650-5
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Sills GJ. Combining antiepileptic drugs--rational polytherapy? Seizure 2011;20:369-75
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Kwan P. Newer drugs for focal epilepsy in adults. BMJ 2012;344:e345
   PubMed Web of Science ®Google Scholar
• Semah F, Picot MC, Adam C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51:1256-62
   PubMed Web of Science ®Google Scholar
• Engel J. A Greater Role for Surgical Treatment of Epilepsy: Why and When? Epilepsy Curr 2003;3:37-40
   PubMedGoogle Scholar
• Wiebe S, Blume WT, Girvin JP, Eliasziw M; Effectiveness, Efficiency of Surgery for Temporal Lobe Epilepsy Study G. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001;345:311-18
   PubMed Web of Science ®Google Scholar
• Engel JJr, McDermott MP, Wiebe S, et al. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA 2012;307:922-30
   PubMed Web of Science ®Google Scholar
• Spencer SS, Berg AT, Vickrey BG, et al. Predicting long-term seizure outcome after resective epilepsy surgery: the multicenter study. Neurology 2005;65:912-18
   PubMed Web of Science ®Google Scholar
• Blumcke I, Coras R, Miyata H, Ozkara C. Defining clinico-neuropathological subtypes of mesial temporal lobe epilepsy with hippocampal sclerosis. Brain Pathol 2012;22:402-11
   PubMed Web of Science ®Google Scholar
• Keller SS, Richardson MP, O’Muircheartaigh J, et al. Morphometric MRI alterations and postoperative seizure control in refractory temporal lobe epilepsy. Hum Brain Mapp 2015;36:1637-47
   PubMed Web of Science ®Google Scholar
• Varoglu AO, Saygi S, Acemoglu H, Ciger A. Prognosis of patients with mesial temporal lobe epilepsy due to hippocampal sclerosis. Epilepsy Res 2009;85:206-11
   PubMed Web of Science ®Google Scholar
• Matagne A, Margineanu DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol 2008;154:1662-71
   PubMed Web of Science ®Google Scholar
• Zona C, Pieri M, Carunchio I, et al. Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture. Epilepsy Res 2010;88:46-54
   PubMed Web of Science ®Google Scholar
• Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacol 2008;54:715-20
   PubMed Web of Science ®Google Scholar
• Detrait ER, Leclercq K, Loscher W, et al. Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats. Epilepsy Res 2010;91:74-83
   PubMed Web of Science ®Google Scholar
• Dupuis N, Matagne A, Staelens L, et al. Anti-ictogenic and antiepileptogenic properties of brivaracetam in mature and immature rats. Epilepsia 2015;56:800-5
   PubMed Web of Science ®Google Scholar
• Mula M, Sander JW, Trimble MR. The role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: a study on levetiracetam. Seizure 2006;15:405-8
   PubMed Web of Science ®Google Scholar
• van Vliet EA, Aronica E, Redeker S, et al. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia 2009;50:422-33
   PubMed Web of Science ®Google Scholar
• von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics 2007;4:84-7
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML, Espie P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispose 2008;36:36-45
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1-43
   PubMed Web of Science ®Google Scholar
• French JA, Costantini C, Brodsky A, et al. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010;75:519-25
   PubMed Web of Science ®Google Scholar
• Van Paesschen W, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2013;54:89-97
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55:47-56
   PubMed Web of Science ®Google Scholar
• Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55:57-66
   PubMed Web of Science ®Google Scholar
• Kwan P, Trinka E, Van Paesschen W, et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014;55:38-46
   PubMed Web of Science ®Google Scholar
• Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007;4:88-96
   PubMed Web of Science ®Google Scholar
• Hebeisen S, Pires N, Loureiro AI, et al. Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide. Neuropharmacol 2015;89:122-35
   PubMed Web of Science ®Google Scholar
• Potschka H, Soerensen J, Pekcec A, et al. Effect of eslicarbazepine acetate in the corneal kindling progression and the amygdala kindling model of temporal lobe epilepsy. Epilepsy Res 2014;108:212-22
   PubMed Web of Science ®Google Scholar
• Almeida L, Minciu I, Nunes T, et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol 2008;48:966-77
   PubMed Web of Science ®Google Scholar
• Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 2012;53:935-46
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovannelli F, Cincotta M, et al. Clinical utility of eslicarbazepine: current evidence. Drug Des Devel Ther 2015;9:781-9
   PubMed Web of Science ®Google Scholar
• Elger C, Bialer M, Cramer JA, et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007;48:497-504
   PubMed Web of Science ®Google Scholar
• Elger C, Halasz P, Maia J, Group BIAIS. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009;50:454-63
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Lopes-Lima J, Almeida L, Group BIAIS. Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009;120:281-7
   PubMed Web of Science ®Google Scholar
• Halasz P, Cramer JA, Hodoba D, et al. Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 2010;51:1963-9
   PubMed Web of Science ®Google Scholar
• Hufnagel A, Ben-Menachem E, Gabbai AA, et al. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res 2013;103:262-9
   PubMed Web of Science ®Google Scholar
• Villanueva V, Serratosa JM, Guillamon E, et al. Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: results of the 1-year ESLIBASE retrospective study. Epilepsy Res 2014;108:1243-52
   PubMed Web of Science ®Google Scholar
• Massot A, Vivanco R, Principe A, et al. Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results. Neurologia 2014;29:94-101
   PubMed Web of Science ®Google Scholar
• Jacobson MP, Pazdera L, Bhatia P, et al. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. BMC Neurol 2015;15:46
   PubMed Web of Science ®Google Scholar
• Sperling MR, Abou-Khalil B, Harvey J, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia 2015;56:244-53
   PubMed Web of Science ®Google Scholar
• Doeser A, Dickhof G, Reitze M, et al. Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. Brain 2015;138:371-87
   PubMed Web of Science ®Google Scholar
• Errington AC, Coyne L, Stohr T, et al. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacol 2006;50:1016-29
   PubMed Web of Science ®Google Scholar
• Czech T, Yang JW, Csaszar E, et al. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res 2004;29:2189-96
   PubMed Web of Science ®Google Scholar
• Stohr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007;74:147-54
   PubMed Web of Science ®Google Scholar
• Brandt C, Heile A, Potschka H, et al. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006;47:1803-9
   PubMed Web of Science ®Google Scholar
• Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics 2007;4:145-8
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17
   PubMed Web of Science ®Google Scholar
• Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53
   PubMed Web of Science ®Google Scholar
• Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958-67
   PubMed Web of Science ®Google Scholar
• Wehner T, Bauer S, Hamer HM, et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009;16:423-5
   PubMed Web of Science ®Google Scholar
• Garcia-Morales I, Delgado RT, Falip M, et al. Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures. Seizure 2011;20:801-4
   PubMed Web of Science ®Google Scholar
• Villanueva V, Lopez-Gomariz E, Lopez-Trigo J, et al. Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA. Epilepsy Behav 2012;23:298-304
   PubMed Web of Science ®Google Scholar
• Novy J, Bartolini E, Bell GS, et al. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation. Epilepsy Res 2013;106:250-6
   PubMed Web of Science ®Google Scholar
• Flores L, Kemp S, Colbeck K, et al. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK). Seizure 2012;21:512-17
   PubMed Web of Science ®Google Scholar
• Villanueva V, Lopez FJ, Serratosa JM, et al. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Epilepsy Behav 2013;29:349-56
   PubMed Web of Science ®Google Scholar
• Villanueva V, Garces M, Lopez-Gomariz E, et al. Early add-on lacosamide in a real-life setting: results of the REALLY study. Clin Drug Invest 2015;35:121-31
   PubMed Web of Science ®Google Scholar
• Franco V, Iudice A, Grillo E, et al. Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. Exp Opin Pharmacother 2014;15:637-44
   PubMed Web of Science ®Google Scholar
• Citraro R, Aiello R, Franco V, et al. Targeting alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. Exp Opin Ther Targets 2014;18:319-34
   PubMed Web of Science ®Google Scholar
• Gillardon F, Bottiger B, Schmitz B, et al. Activation of CPP-32 protease in hippocampal neurons following ischemia and epilepsy. Brain research Molecular brain research 1997;50:16-22
   PubMedGoogle Scholar
• Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11:56-63
   PubMed Web of Science ®Google Scholar
• De Sarro G, Gitto R, Russo E, et al. AMPA receptor antagonists as potential anticonvulsant drugs. Curr Topics Med Chem 2005;5:31-42
   PubMed Web of Science ®Google Scholar
• Russo E, Gitto R, Citraro R, et al. New AMPA antagonists in epilepsy. Exp Opin Invest Drugs 2012;21:1371-89
   PubMed Web of Science ®Google Scholar
• Szenasi G, Vegh M, Szabo G, et al. 2,3-benzodiazepine-type AMPA receptor antagonists and their neuroprotective effects. Neurochem Intern 2008;52:166-83
   PubMed Web of Science ®Google Scholar
• Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331-40
   PubMed Web of Science ®Google Scholar
• Ceolin L, Bortolotto ZA, Bannister N, et al. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Intern 2012;61:517-22
   PubMed Web of Science ®Google Scholar
• Hanada T, Ido K, Kosasa T. Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect 2014;2:e00063
   PubMedGoogle Scholar
• Twele F, Bankstahl M, Klein S, et al. The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. Neuropharmacol 2015;95:234-42
   PubMed Web of Science ®Google Scholar
• Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia 2015;56:12-27
   PubMed Web of Science ®Google Scholar
• Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125:8-15
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54:117-25
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589-96
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15
   PubMed Web of Science ®Google Scholar
• Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126:263-9
   PubMed Web of Science ®Google Scholar
• Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia 2013;54:126-34
   PubMed Web of Science ®Google Scholar
• Blackburn-Munro G, Dalby-Brown W, Mirza NR, et al. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005;11:1-20
   PubMedGoogle Scholar
• Wuttke TV, Seebohm G, Bail S, et al. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-17
   PubMed Web of Science ®Google Scholar
• Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-9
   PubMed Web of Science ®Google Scholar
• Mazarati A, Wu J, Shin D, et al. Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia 2008;49:1777-86
   PubMed Web of Science ®Google Scholar
• Rostock A, Tober C, Rundfeldt C, et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-23
   PubMed Web of Science ®Google Scholar
• De Sarro G, Di Paola ED, Conte G, et al. Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naunyn-Schmiedeberg’s Arch Pharmacol 2001;363:330-6
   Google Scholar
• Tompson DJ, Crean CS. The interaction potential of retigabine (ezogabine) with other antiepileptic drugs. Curr Clini Pharmacol 2014;9:148-56
   PubMedGoogle Scholar
• Tompson DJ, Crean CS. Clinical pharmacokinetics of retigabine/ezogabine. Curr Clini Pharmacol 2013;8:319-31
   PubMedGoogle Scholar
• French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-63
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-24
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Brodie MJ, Leroy R, et al. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies. Epilepsy Res 2012;102:117-21
   PubMed Web of Science ®Google Scholar
• Wehner T, Chinnasami S, Novy J, et al. Long term retention of retigabine in a cohort of people with drug resistant epilepsy. Seizure 2014;23:878-81
   PubMed Web of Science ®Google Scholar
• Garin Shkolnik T, Feuerman H, Didkovsky E, et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol 2014;150:984-9
   PubMed Web of Science ®Google Scholar
• Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012;53:412-24
   PubMed Web of Science ®Google Scholar
• Large CH, Sokal DM, Nehlig A, et al. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia 2012;53:425-36
   PubMed Web of Science ®Google Scholar